Paying for formerly free medicines in Spain after 1 year of co-payment: Changes in the number of dispensed prescriptions

Applied Health Economics and Health Policy

Volumn 12, Issue 3, 2014, Pages 279-287

  Puig Junoy, Jaume ^a   Rodríguez Feijoó, Santiago ^b   Lopez Valcarcel, Beatriz G ^b  

^a DEPARTMENT OF ECONOMICS AND BUSINESS   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST CONTROL; DRUG COST; EMERGENCY HEALTH SERVICE; FEE; HEALTH CARE POLICY; HOSPITAL SERVICE; HUMAN; INCOME; INSURANCE; PENSIONER; PHARMACY; PRESCRIPTION; SPAIN; COST; ECONOMICS; EPIDEMIOLOGY; FINANCIAL MANAGEMENT; STATISTICS AND NUMERICAL DATA;

PRESCRIPTION DRUG;

COST SHARING; DRUG COSTS; FINANCING, PERSONAL; HEALTH POLICY; HUMANS; PRESCRIPTION DRUGS; SPAIN;

EID: 84901677686     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0097-6     Document Type: Article

References (21)

1. Legido-Quigley H, Otero L, la Parra D, Alvarez-Dardet C, Martin-Moreno JM, McKee M. Will austerity cuts dismantle the Spanish healthcare system? BMJ. 2013;346:f2363.
2. Urbanos R, González B, Puig-Junoy J. La crisis económica llega a la sanidad. Economistas 2012;131:158-67.
3. Thomson S, Mossialos E. Primary care and prescription drugs: coverage, cost-sharing, and financial protection in six European countries. Issue Brief (Commonw Fund) 2010;82:1-14.
4. Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers 461. Belgium: European Commission; 2012 Sep.
5. Vandoros S, Stargardt T. Reforms in the Greek pharmaceutical market during the financial crisis. Health Policy. 2013;109:1-6.
6. Smith PC. Universal health coverage and user charges. Health Econ Policy Law. 2013;8(4):529-35.
7. Richards M. Extent and causes of international variation in drug usage. A report to the Secretary of State for Health 2010. https://www.gov.uk/ government/uploads/system/uploads/attachment-data/file/151987/dh-117977.pdf. Accessed 23 March 2014.
8. Puig-Junoy J, García-Gómez P, Casado-Marín D. Free medicines thanks to retirement: moral hazard and hospitalization offsets in an NHS. TinBergen Institute Discussion Paper TI 2011-108/3. http://papers. tinbergen.nl/11108.pdf. Accessed 2014 Mar 25.
9. Cabiedes L, Ortún V. Prescriber incentives. Chapter 9. In: Puig-Junoy J, editor. The public financing of pharmaceuticals. Northampton: Edward Elgar Publishing; 2005.
10. Meneu R, Peiró S. Elementos para la gestión de la prescripción y la prestación farmacéutica. Barcelona: Masson Ed; 2004.
11. Xu KT, et al. Over-prescribing of antibiotics and imaging in the management of uncomplicated URIs in emergency departments. BMC Emerg Med. 2013;13:7.
12. Sanfelix-Gimeno G, Peiro S, et al. Pharmaceutical prescription in primary care. SESPAS report 2012 [in Spanish]. Gac Sanit. 2012;26(Suppl 1):41-5.
13. Puig-Junoy J. Paying for free healthcare. The role of prices in our healthcare decisions. Barcelona: Libros del Lince; 2013.
14. Ministerio de Sanidad, Servicios Sociales e Igualdad. http://www.msssi.gob.es/. Accessed 23 March 2014.
15. Box GEP, Jenkins GM, Reinsel GC. Time series analysis: forecasting and control. 4th ed. San Francisco: Willey; 2008.
16. OECD. Health at a glance 2013: OECD indicators. Paris: OECD Publishing; 2013.
17. Laroche M-L, et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol. 2007;63(2):177-86. (Pubitemid 46072104)
18. Ellis RP. Five questions for health economists. Int J Health Care Finance Econ. 2012;12:217-33.
19. Moreno-Torres I, Puig-Junoy J, Raya JM. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain. Eur J Health Econ. 2011;12:563-73.
20. van de Vooren K, Curto A, Garattini L. Optional copayments on anti-cancer drugs. BMJ. 2012;346:f349.
21. Chandra A, Gruber J, McKnight R. Patient cost sharing in low income populations. Am Econ Rev: P&P 2010;100:303-8.